[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"focal-segmental-glomerulosclerosis-fsgs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:focal-segmental-glomerulosclerosis-fsgs":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,72,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640089","phase-2-evaluate-the-efficacy-safety-pharmacokinetics-and-pharmacodynamics-of-ever001-in-participants-with-selected-proteinuric-glomerular-diseases-100640089",false,"NCT07614477","Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases","The Sub-Study 3 of A Phase 1b\u002F2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases (ES108001)","Inclusion Criteria:\n\n* Primary FSGS or MCD\u002FIgAN confirmed by renal biopsy\n* eGFR ≥ 45 mL\u002Fmin\u002F1.73 m²\n* For participants with FSGS or MCD: must have a 24-hour urine protein-to-creatinine ratio (UPCR) \\> 3.5 g\u002Fg and serum albumin \\\u003C 30 g\u002FL during the screening period\n* For participants in the IgAN group: 24-hour UPCR ≥ 0.8 g\u002Fg; ARB or ACEI stable for ≥ 12 weeks prior to Day 1\n* Patients with FSGS or MCD who have not been treated with immunosuppressants or are sensitive to prior immunosuppressant treatment\n\nExclusion Criteria:\n\n* Hereditary or secondary FSGS\u002FMCD; collapsing FSGS\n* BMI ≥ 35 kg\u002Fm² in participants with FSGS\u002FMCD\n* Evidence of diabetes mellitus or a history of diabetes mellitus\n* Acute or chronic infection requiring treatment\n* Patients infected with HIV, hepatitis C, syphilis, or hepatitis B\n* Patients with current or prior inadequately treated active tuberculosis (TB), latent TB, or evidence of current household contact with active TB\n* At risk of bleeding\n* Baseline 24-hour UPCR \\> 3 g\u002Fg and serum albumin \\\u003C 30 g\u002FL in participants with IgAN","ALL","18 Years","75 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a Phase 1b\u002F2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN. EVER001 acts on multiple immune pathways without directly affecting T cells or depleting B cells (both are lymphocytes). The study will be conducted at \\~30 centers in China, enrolling 45 participants aged 18-75 years (15 per indication). The IMP is a 100 mg oral capsule, dosed at 200 mg twice daily (2 capsules per dose, 4 daily) for 52 weeks.",[27,28,29],"Minimal Change Disease (MCD)","IgA Nephropathy (IgAN)","Focal Segmental Glomerulosclerosis (FSGS)","RECRUITING","2026-05-22",{"date":33,"type":34},"2026-05-29","ACTUAL",{"date":36,"type":21},"2026-05-15",{"date":38,"type":21},"2029-03-31",{"name":40,"class":41},"Everest Medicines (China) Co.,Ltd.","INDUSTRY",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100632690","slit-abs-study-on-patients-with-autoimmune-podocytopathy-100632690","NCT07516964","SLIT ABS: Study on Patients With Autoimmune Podocytopathy","Validation and Implementation of Diagnostic Techniques for the Detection of Circulating Factors in Patients With Autoimmune Podocytopathy","Inclusion Criteria:\n\n* Pediatric and adult patients with a diagnosis of podocytopathy\n* Patients with nephrotic syndrome and\u002For histological diagnosis of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), collapsing glomerulopathy (CG), or diffuse mesangial sclerosis (DMS)\n* Both newly diagnosed (incident) patients and patients already under follow-up at participating centers\n* Availability of clinical data from medical records (including paper and\u002For electronic records, laboratory reports, and discharge summaries)\n* Availability of biological samples (e.g., blood and\u002For renal biopsy), if collected as part of routine clinical care\n* Signed informed consent by the patient or legal guardian (and assent when applicable)\n\nExclusion Criteria:\n\n* Refusal or inability of the patient, parents, or legal guardian to provide informed consent\n* Lack of sufficient clinical data or unavailable biological samples required for the study","0 Years","99 Years",{"count":53,"type":21},50,[55],"NA","Nephrotic syndrome is a kidney condition that mainly affects children and is characterized by high levels of protein in the urine, low levels of protein in the blood, and swelling. While many children respond well to steroid treatment, a large proportion experience relapses or become dependent on therapy. In some cases, the disease does not respond to standard treatments and may progress to chronic kidney disease.\n\nRecent research suggests that, in addition to genetic factors, immune system mechanisms may play a key role in the development and progression of nephrotic syndrome. In particular, some patients produce autoantibodies against nephrin, an essential protein of the kidney filtration barrier. These autoantibodies may be associated with disease activity and treatment response.\n\nThe aim of this study is to investigate the presence of anti-nephrin autoantibodies in children with nephrotic syndrome and to better understand their role in disease mechanisms and clinical outcomes.The study will also explore the presence of other autoantibodies targeting components of the glomerular filtration barrier. The study will use advanced laboratory techniques, including blood tests and detailed analysis of kidney biopsy samples, to identify these antibodies and their relationship with kidney structure and function.\n\nBy integrating laboratory findings with clinical data, this study aims to improve the understanding of nephrotic syndrome and support the development of more personalized diagnostic and therapeutic strategies, with the goal of improving patient outcomes and reducing unnecessary or ineffective treatments.",[58,59,29,60],"Nephrotic Syndrome With Edema (Diagnosis)","Minimal Change Nephrotic Syndrome","Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy","2026-04-01",{"date":63,"type":34},"2026-04-08",{"date":65,"type":34},"2025-06-10",{"date":67,"type":21},"2036-10",{"name":69,"class":70},"Meyer Children's Hospital IRCCS","OTHER",14,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100631363","phase-2-a-clinical-study-of-bat4406f-injection-in-patients-with-minimal-change-diseasefocal-segmental-glomerulosclerosis-100631363","NCT07499700","A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease\u002FFocal Segmental Glomerulosclerosis","A Phase II\u002FIII Clinical Study Evaluating the Efficacy and Safety of BAT4406F Injection in Patients With Minimal Change Disease\u002FFocal Segmental Glomerulosclerosis","Inclusion Criteria:\n\n1. Clinically diagnosed with NS, with a pathological diagnosis of Minimal change disease\u002FFocal segmental glomerulosclerosis confirmed by renal biopsy within 7 years (Minimal change disease) or 10 years (Focal segmental glomerulosclerosis) prior to screening, and who are responsive to corticosteroid therapy\n2. The time since achieving complete remission following corticosteroid therapy for the most recent active or relapsed disease is within 8 weeks of baseline\n\nExclusion Criteria:\n\n1. Secondary Nephrotic Syndrome\n2. Known genetic defects associated with Nephrotic Syndrome or a family history of Nephrotic Syndrome\n3. Receipt of any B-cell depletion or B-cell-modifying therapy within 6 months prior to baseline\n4. History of allergy to monoclonal antibodies; or a predisposition to allergies\n5. Received treatment with immunosuppressants within 60 days prior to baseline\n6. Received immunoglobulin within 90 days prior to baseline; or received immunomodulators such as thymosin within 4 weeks prior to baseline\n7. Participation in a clinical trial of another investigational drug within 90 days prior to baseline or within 5 half-lives of the drug (whichever is longer), or plans to participate in a clinical trial of another drug during the study period\n8. Marked abnormalities in liver or kidney function\n9. Positive for hepatitis B surface antigen (HBsAg); or positive for hepatitis C virus (HCV) antibodies; or positive for Treponema pallidum antibodies; or history of Human Immunodeficiency Virus or positive for Human Immunodeficiency Virus antibodies",{"count":80,"type":21},192,[24,82],"PHASE3","This is a phase II\u002FIII multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease\u002FFocal Segmental Glomerulosclerosis",[27,29],"2026-03-29",{"date":87,"type":34},"2026-04-03",{"date":89,"type":34},"2025-10-26",{"date":91,"type":21},"2030-11-26",{"name":93,"class":41},"Bio-Thera Solutions",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":94},"100574558","raman-spectroscopy-diagnosis-of-kidney-diseases-100574558","NCT06760845","Raman Spectroscopy Diagnosis of Kidney Diseases","Research on Raman Spectroscopy Detection Technology in Kidney Disease Diagnosis","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. Patients diagnosed with IgA nephropathy, idiopathic membranous nephrop, diabetic nephropathy, or focal segmental glomerulosclerosis confirmed by renal biopsy;\n3. Patients who have not received hormone and\u002For immunosup therapy before the renal biopsy;\n\nExclusion Criteria:\n\n1. Presence of factors causing secondary membranous nephropathy: such as autoimmune diseases (systemic lupus erythematosus),\u002Finfections (viral hepatitis), drugs or toxins, etc.;\n2. Severe infection: clinical manifestations such as fever, cough and sputum, throat, abdominal pain, diarrhea, boils and other skin and soft tissue infections, with white blood cell count in blood routine exceeding the normal range (10×09\u002FL);\n3. Severe cardiovascular disease: including chronic heart failure of grade 3 or above and various arrhythmias;\n4. Infect diseases: active phase of various types of hepatitis, AIDS, syphilis, etc.;\n5. Evidence of tumor: already diagnosed with a certain tumor or manifestations, tumor markers, etc. indicating the possibility of a tumor;\n6. Patients with incomplete data or missed diagnosis.",true,{"count":104,"type":21},200,"OBSERVATIONAL","This research plan, from January 2021 to December 2024, aims to collect serum and morning urine from patients diagnosed with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis the Nephrology Department of Qianfoshan Hospital in Shandong Province, through renal biopsy. These samples will be scanned using a Raman spect to obtain Raman spectral data. The scattering peaks in the Raman spectra will be analyzed using Origin software for Gaussian curve fitting. The position of the peaks will used to query relevant literature to identify the corresponding chemical bonds and confirm the presence of compounds.\n\nThe intensity and area of the chemical substance peaks in the Raman will be calculated and used to plot calibration curves, thereby establishing a quantitative analysis equation. This equation will be used to accurately calculate the concentration of each analyte in serum and urine samples. Based on the average concentration data for each patient group, multivariate analysis methods, such as principal component analysis (PCA) and Mahalanis distance discriminant model, will be used to classify and predict the disease types.\n\nThe preliminary data for this study comes from the Nephrology Department ofianfoshan Hospital, where different types of glomerular diseases have been pathologically classified using tools such as light microscopy, electron microscopy, and immunoforescence microscopy. By combining Raman spectroscopy technology and statistical analysis, this study aims to establish a non-invasive and efficient diagnostic tool to assist in the of kidney diseases and predict treatment outcomes.",[28,108,109,29],"Membranous Nephropathy","Diabetic Nephropathy","2025-01-06",{"date":112,"type":34},"2025-01-07",{"date":114,"type":34},"2021-02-01",{"date":116,"type":21},"2025-07",{"name":118,"class":70},"Zunsong Wang"]